Bristol Myers Squibb Co (BMY) EBIT Margin (2009 - 2026)
Bristol Myers Squibb (BMY) posted quarterly EBIT Margin of 2.77% for Q2 2026, up 1581.0% year-over-year from 0.17% in Q2 2025, and up 275.18% quarter-over-quarter from 1.58% in Q1 2026.
Bristol Myers Squibb Co (BMY) EBIT Margin (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (BMY) has reported EBIT Margin for 18 consecutive years, with 2.77% the latest figure, recorded in Q2 2026.
- In Q2 2026, EBIT Margin rose 1581.0% year-over-year to 2.77%; the TTM figure through Jun 2026 stood at 5.63% (up 1026.0% YoY), while the FY2025 annual figure was 9.56%, up 3671.0% from the prior year.
- EBIT Margin climbed to 2.77% in Q2 2026 per BMY's latest filing, from 1.58% in the prior quarter.
- Across five years, EBIT Margin topped out at 2.77% in Q2 2026 and bottomed at 121.77% in Q1 2024.
- Historically, EBIT Margin has averaged 14.62% across 5 years, with a median of 6.58% in 2022.
- Annual changes were most pronounced in 2024 — EBIT Margin slumped 12357 bps — and 2025, when it surged 12122 bps.
- Bristol Myers Squibb's EBIT Margin stood at 6.44% in 2022, then sank by 45 bps to 9.33% in 2023, then slumped by 303 bps to 37.57% in 2024, then soared by 44 bps to 21.01% in 2025, then surged by 113 bps to 2.77% in 2026.
- Business Quant data shows BMY's EBIT Margin at 2.77% in Q2 2026, 1.58% in Q1 2026, and 21.01% in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.77% |
| Mar 31, 2026 | -1.58% |
| Dec 31, 2025 | -21.01% |
| Sep 30, 2025 | -2.63% |
| Jun 30, 2025 | -13.03% |
| Mar 31, 2025 | -0.55% |
| Dec 31, 2024 | -37.57% |
| Sep 30, 2024 | -10.77% |
| Jun 30, 2024 | -16.24% |
| Mar 31, 2024 | -121.77% |
| Dec 31, 2023 | -9.33% |
| Sep 30, 2023 | -3.36% |
| Jun 30, 2023 | -9.06% |
| Mar 31, 2023 | 1.80% |
| Dec 31, 2022 | -6.44% |
| Sep 30, 2022 | -1.28% |
| Jun 30, 2022 | -6.41% |
| Mar 31, 2022 | -6.73% |
| Dec 31, 2021 | -4.16% |
| Sep 30, 2021 | -1.15% |